Home > Healthcare > Pharmaceuticals > Finished Drug Form > methicillin resistant staphylococcus aureus drugs market
Get a free sample of Methicillin-resistant Staphylococcus Aureus Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Methicillin-resistant Staphylococcus Aureus Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The methicillin-resistant staphylococcus aureus drugs industry is characterized by the presence of leading pharmaceutical companies. The key market players include Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., and Novartis AG which are focused on developing improved treatments, such as longer-acting formulations and innovative therapies. Market players compete on factors like efficacy, safety, patient convenience, and cost-effectiveness.
Prominent players operating in the methicillin-resistant staphylococcus aureus drugs industry include:
The global methicillin-resistant staphylococcus aureus (MSRA) drugs market was valued at USD 4.1 billion in 2023 and is anticipated to grow at 4.2% CAGR between 2024
The glycopeptides segment in the MSRA drugs market reached USD 1.2 billion in 2023, owing to their broad-spectrum activity against gram-positive bacteria, including MRSA, and their established efficacy in treating severe MRSA infections.
North America methicillin-resistant staphylococcus aureus drugs market is anticipated to grow at 3.9% CAGR till 2032, attributed to advanced healthcare infrastructure, high awareness levels about infectious diseases, and robust research and development activities.
AbbVie Inc., Basilea Pharmaceutica Ltd, Baxter International Inc., Cumberland Pharmaceuticals Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.